Original Article

Impact of occlusion duration on the success rate and outcomes of percutaneous coronary intervention in chronic total occlusions

Antonio de Castro Filho*, Edgar Stroppa Lamas, Mário Barbosa G. Nunes, Dimytri A. Siqueira, Rodolfo Staico, Daniel Chamié, J. Ribamar Costa Jr., Ricardo A. Costa, Alexandre Abizaid

Instituto Dante Pazzanese de Cardiologia, São Paulo, SP, Brazil

ARTICLE INFO

Article history: Received 1 June 2015 Accepted 11 August 2015

Keywords: Coronary artery disease Percutaneous coronary intervention Coronary occlusion

ABSTRACT

Background: Initial studies have shown that old occlusions or those with indeterminate occlusion duration have been associated with percutaneous coronary intervention (PCI) failure and a worse prognosis. This study aimed to determine the impact of occlusion duration on the success and outcomes of contemporary PCI on chronic total occlusion (CTO).

Methods: The authors analyzed a retrospective cohort of consecutive patients submitted to PCI in CTO, who were compared according to the confirmed occlusion duration (COD) < 12 months, \geq 12 months, or indeterminate occlusion duration (IOD).

Results: A total of 168 patients were treated, 122 (72.6%) with COD (80 < 12 months, $42 \ge 12$ months) and 46 (24.7%) with an IOD. Lesion extension was 17.0 ± 13.6 mm, in 2.90 ± 0.58 mm vessels, and the anterograde approach was used in 98.8% of cases. Angiographic success was attained in 79.2% of patients (80.0% vs. 73.8% vs. 82.6%; p = 0.73). The main cause of failure was the inability to cross the lesion with the guidewire (68.6%). Occlusion duration had no impact on in-hospital events (4.8% vs. 7.1% vs. 6.0%; p = 0.73), which were almost entirely explained by periprocedural myocardial infarction, or on late outcomes (18.8% vs. 7.1% vs. 15.3%; p = 0.23). At the multivariate analysis, lesion length ≥ 20 mm (odds ratio - OR = 7.27; 95% confidence interval - 95% IC 1.94-29.1; p = 0.003), calcification (OR = 4.72; 95% CI 1.19-19.1; p = 0.02), and tortuosity of the occluded segment (OR = 15.98; 95% CI 2.18-144.7; p = 0.007) were predictors of failure.

Conclusions: Occlusion duration was not associated with increased failure rate of the procedure or worse PCI outcomes in CTO.

© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Impacto do tempo de oclusão na taxa de sucesso e nos resultados da intervenção coronária percutânea em obstruções totais crônicas

RESUMO

Palavras-chave:
Doença da artéria coronariana
Intervenção coronária percutânea
Oclusão coronária

Introdução: Estudos iniciais mostram que oclusões antigas ou com tempo indeterminado têm sido associadas a insucesso da intervenção coronária percutânea (ICP) e a pior prognóstico. Nosso objetivo foi determinar o impacto do tempo de oclusão no sucesso e nos resultados da ICP contemporânea na obstrução total crônica (OTC).

Métodos: Analisamos uma coorte retrospectiva de pacientes consecutivos que realizaram ICP em OTC, e que foram comparados de acordo com o tempo de oclusão confirmado (TOC) < 12 meses, ≥ 12 meses, ou indeterminado (TOI).

Resultados: Foram tratados 168 pacientes, 122 (72,6%) com TOC (80 < 12 meses, $42 \ge 12$ meses) e 46 (24,7%) com TOI. A extensão da lesão foi de 17,0 \pm 13,6 mm, em vasos de 2,90 \pm 0,58 mm, e a abordagem anterógrada foi utilizada em 98,8% dos casos. Sucesso angiográfico foi obtido em 79,2% dos pacientes (80,0% vs. 73,8% vs. 82,6%; p = 0,73). A principal causa de insucesso foi a incapacidade de cruzar a lesão com o fio-guia (68,6%). O tempo de oclusão não teve impacto na taxa de eventos cardiovasculares hospitalares (4,8% vs. 7,1% vs. 6,0%; p = 0,73), explicados em sua quase totalidade pelos infartos do miocárdio periprocedimento, ou nos eventos tardios (18,8% vs. 7,1% vs. 15,3%; p = 0,23). Na análise multivariada, comprimento da lesão \ge 20 mm ($odds\ ratio$ - OR = 7,27; intervalo de confiança de 95% - IC 95% 1,94-29,1; p = 0,003), calcificação (OR = 4,72; IC 95% 1,19-19,1; p = 0,02) e tortuosidade do segmento ocluído (OR = 15,98; IC 95% 2,18-144,7; p = 0,007) foram preditores de insucesso.

DOI of original article: http://dx.doi.org/10.1016/j.rbci.2016.06.006

^{*} Corresponding author: Serviço de Cardiologia Invasiva do Instituto Dante Pazzanese de Cardiologia, Avenida Dr. Dante Pazzanese, 500, Vila Mariana, CEP: 04012-180, São Paulo. SP. Brasil.

E-mail: afilhocastro@gmail.com (A. Castro Filho).

Peer review under the responsibility of Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista.

Conclusões: O tempo de oclusão não está associado ao aumento da taxa de insucesso do procedimento ou a piores resultados da ICP em OTC.

© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Publicado por Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Chronic total occlusion (CTO) is found in approximately 15 to 30% of patients referred for elective coronary angiography.1 However, percutaneous coronary intervention (PCI) for CTO corresponds to only 10% of the total procedures^{2,3} and remains one of the most challenging interventions in the field. In fact, the number of percutaneous procedures in CTO has remained stable in recent years,4 despite the development of new techniques such as the retrograde approach, the use of new dedicated devices, and the increased experience of interventionists, resulting in increasingly higher success rates.5-8 It is known that a myocardial area irrigated by an occluded artery may be associated with persistent ischemia, even in the presence of well-developed collaterals,9 and that the successful revascularization of the lesion is associated with reduced ischemic burden and improved ventricular contractility.10 Studies have shown the improvement in late prognosis of patients submitted to successful PCI compared to those with procedural failure.11-14 The main reason for this failure is the inability to cross the lesion with the guidewire or the balloon. Initial studies have shown that a long occlusion duration is associated with failure of the technique. 15,16 Similarly, an indeterminate occlusion duration (IOD) is also associated with PCI failure.¹⁷ Conversely, a more recent study showed no association between the occlusion duration and the success rate of the procedure.18

The aim of this study was to determine the impact of occlusion duration on the success and outcomes of contemporary PCI in CTO.

Methods

Study population

A retrospective cohort of consecutive patients submitted to PCI in occlusive lesions was assessed from June 2008 to December 2014 in a tertiary cardiology reference hospital linked to the Brazilian Unified Health System (SUS, acronym in Portuguese). After the review of medical records and analysis of coronary angiography, patients who had estimated occlusion duration < 3 months or antegrade coronary flow, with Thrombolysis in Myocardial Infarction (TIMI) > 0, were excluded.

Definitions

CTO was defined as TIMI grade 0 flow in the occluded segment, with estimated occlusion duration > 3 months.^{19,20} The levels of certainty of occlusion duration followed the definitions of the European Consensus Euro CTO Club:¹⁹ confirmed occlusion duration (COD) in patients with angiographic evidence of occlusion > 3 months or objective evidence of acute myocardial infarction (AMI) in the occluded coronary > 3 months before the coronary angiography; or IOD in patients with coronary occlusion with TIMI grade zero flow and anatomy suggestive of long-term occlusion (presence of collaterals or absence of contrast retention) with ischemic symptoms unaltered in the last 3 months or evidence of silent ischemia.

Collateral circulation was classified according to Rentrop et al.:²¹ grade 0, if there was no visible collateral filling; grade 1, if there was filling of lateral branches of the infarct-related artery, without reaching the epicardial segment; grade 2, if there was partial filling of the epicardial vessel; and grade 3, if there was complete filling of the collateral vessel promoted by the collaterals.

Angiographic success was defined as final residual stenosis < 20% with distal TIMI 3 flow. AMI was defined as an increase in creatine kinase MB isoenzyme (CK-MB) > 3 times the upper limit of normal, associated with electrocardiographic findings and/or symptoms suggestive of ischemia (periprocedural AMI) or increased CK-MB or troponin levels above the 99th percentile of a reference control population (spontaneous AMI). New target vessel revascularization (TVR) was defined as repeat PCI or bypass graft placement for restenosis at the lesion treated during index PCI due to symptoms and/or functional tests, with demonstration of ischemia in the corresponding territory. Contrast-induced nephropathy was defined as an absolute increase in serum creatinine level of 0.5 mg/dL or a 25% increase compared to basal level within 48 hours of the procedure.²²

Procedure

PCI was performed according to standardized techniques. 19,20 The procedure was indicated for patients with angina or ischemic equivalent and/or ischemia proven in functional tests, being elective in all cases. All patients received acetylsalicylic acid (loading dose of 200 mg and maintenance dose of 100 mg daily) and clopidogrel (loading dose of 300 mg and maintenance dose of 75 mg daily). Unfractionated heparin, at a dose of 100 U/kg, was used to maintain an activated clotting duration > 250 seconds throughout the procedure. The use of glycoprotein IIb/IIIa inhibitors during the procedure was at the discretion of the interventionist, as well as the selection of access route and type of stent. Low-osmolality ionic contrast medium (ioxaglate) was used in all cases, and patients with clearance < 60 mL/minute received isotonic (0.9%) saline for at least 6 hours before and 12 hours after the intervention. Acetylsalicylic acid was maintained indefinitely and clopidogrel was maintained for at least 1 month after bare-metal stents, or 12 months after acute coronary syndrome or when a drug-eluting stent was implanted.

Analyzed outcomes

The primary objective was to evaluate the success rate of the procedure, according to the estimated occlusion duration. The patients were divided into three groups for analysis: < 12 months, ≥ 12 months, or indeterminate. The analyzed secondary outcomes included in-hospital complications and combined major adverse cardiovascular events (MACE), defined as occurrence of death from all causes, AMI, or new TVR, both in-hospital and at the follow-up. Additionally, the authors analyzed MACE at the end of follow-up, according to procedural success or failure.

Coronary angiography was reviewed by two independent interventional cardiologists to determine the anatomical characteristics of lesions and vessels using QAngio® XA software, version 7.3 (Medis

Medical Imaging Systems BV, Leiden, the Netherlands) for the quantitative angiography analysis.

Statistical analysis

Continuous variables are shown as mean ± standard deviation or median and interquartile range, and compared using analysis of variance (ANOVA) or Kruskal-Wallis test, when they showed non-normal distribution. Categorical variables are shown as absolute numbers and percentages and compared using the chi-squared test or Fisher's exact test, as appropriate. The cumulative probability of MACE was obtained using Kaplan-Meier curves and the difference between groups was calculated by the log-rank test.

Predictors of angiographic failure were identified using binary logistic regression, including the following variables: diabetes mellitus, chronic renal failure, left ventricular dysfunction, multivessel coronary disease, tortuosity in the occlusion segment, presence of calcification, blunt stump, presence of bridge collaterals, presence of lateral branch at the site of occlusion, occlusion length ≥ 20 mm, vessel diameter ≤ 2.5 mm, ostial location, occluded coronary artery, and estimated occlusion duration. Variables that showed p < 0.10 in the univariate analysis were used in the multivariate model.

Two-tailed *p*-values < 0.05 were considered statistically significant. Analyses were performed using the R software, version 3.1 (The R Foundation for Statistical Computing, 2014, Vienna, Austria).

Results

Of the 328 analyzed patients with occlusive lesions, 168 met the criteria established for COD > 3 months and were selected. A total of 122 patients (72.6%) met the definitions for COD, of whom 80 had duration < 12 months and $42 \ge 12$ months, whereas 46 (27.4%) met the definitions for IOD. The occlusion duration in the group with COD showed a median of 6.0 months (interquartile range: 4.0 to 12.0 months) and ranged from 3 to 144 months (Fig. 1A). The mean age of the population was 59.2 ± 9.5 years, with a predomi-

nance of males (70.2%), presence of diabetes mellitus in 29.8% of patients, and 18.5% had chronic renal failure.

Patients with $COD \ge 12$ months had a higher prevalence of smoking and chronic renal failure, whereas patients in the group with COD < 12 months had lower prevalence of previous PCI. Most patients were receiving drug therapy for stable coronary disease, with a higher rate of vasodilators in the group with $COD \ge 12$ months (Table 1).

The most commonly treated artery was the left anterior descending artery (42.3%), followed by the right coronary artery (41.1%) and the left circumflex artery (Table 2). No significant difference was observed between groups regarding patients' angiographic characteristics, except in the distribution of lesion location (p=0.02), although there was no difference regarding the ostial location of lesions. Multivessel coronary artery disease was present in 44.6% of patients. The lesions had an occlusive segment on average 17.0 \pm 13.6 mm long in vessels of 2.90 \pm 0.58 mm in diameter. Collateral circulation grade 2 or 3 was present in approximately 90% of patients.

As for the procedural data (Table 3), the 6 F sheath was used in 94.6% of cases and the femoral access, in 58.9%. The antegrade approach was used in most cases (98.8%). A total of 152 stents was implanted in 133 patients, with a mean of 1.2 ± 0.8 stents implanted per lesion, with no significant difference between the groups. The most often used stent was the drug-eluting stent, especially in the groups with COD \geq 12 months (89.7%; p < 0.001). During the procedure, 124.2 ± 61.2 mL of contrast were used, with use of larger volumes in the group with COD \geq 12 months, when compared with the group with COD \leq 12 months and IOD (117.2 mL vs. 144.2 mL vs. 118.3 mL; p = 0.02). The main cause of procedural failure was the inability to cross the lesion with the guidewire (68.6%).

Angiographic success was achieved in 79.2% of cases, with no significant difference between groups (80.0% vs. 73.8% vs. 82.6%; p = 0.73; Fig. 1B). Regarding in-hospital complications, there was no significant difference between the groups regarding MACE (4.8% vs. 7.1% vs. 6.0%; p = 0.73), which was explained almost entirely by periprocedural AMI. There were no deaths and only one TVR was observed due to a stent thrombosis that occurred hours after the procedure. There were three coronary perforations,




Figure 1. (A) Number of patients with chronic total occlusions, according to the occlusion duration. (B) Angiographic success rate, according to the estimated occlusion duration. PCI: percutaneous coronary intervention.

Table 1 Clinical and demographic characteristics.

		COD (n	COD (n = 122)		
Characteristic	Total (n = 168)	< 12 months (n = 80)	≥ 12 months (n = 42)	IOD (n = 46)	<i>p</i> -value
Age, years	59.2 ± 9.5	58.9 ± 8.9	60.4 ± 9.7	60.9 ± 10.1	0.24
Male gender, n (%)	118 (70.2)	52 (65.0)	31 (73.8)	35 (76.1)	0.35
Diabetes mellitus, n (%)	50 (29.8)	25 (31.2)	16 (38.1)	9 (19.6)	0.15
Arterial hypertension, n (%)	148 (88.1)	71 (88.7)	38 (90.5)	39 (84.8)	0.69
Dyslipidemia, n (%)	123 (73.2)	59 (73.8)	33 (78.6)	31 (67.4)	0.49
Smoking, n (%)	87 (51.8)	38 (47.5)	29 (69.0)	20 (43.5)	0.03
Chronic renal failure, n (%)	31 (18.5)	7 (8.7)	14 (33.3)	10 (21.7)	0.003
Previous PCI, n (%)	19 (11.3)	4 (5.0)	7 (16.7)	8 (17.4)	0.04
Left ventricular dysfunction, n (%)	35 (20.8)	23 (28.7)	6 (14.3)	6 (13.0)	0.054
Clinical presentation, n (%)					0.003
Asymptomatic	52 (31.0)	21 (26.3)	8 (19.0)	23 (50.0)	
Stable angina	116 (69.0)	59 (73.8)	34 (81.0)	23 (50.0)	
Medication, n (%)					
Acetylsalicylic acid	167 (99.4)	79 (98.8)	42 (100)	46 (100)	0.57
Beta-blocker	139 (82.7)	68 (85.0)	38 (90.5)	33 (71.7)	0.051
ACEI/ARB	151 (89.9)	75 (93.8)	35 (83.3)	41 (89.1)	0.18
Statin	161 (95.8)	79 (98.8)	38 (90.5)	44 (95.7)	0.09
Vasodilator	35 (20.8)	13 (16.3)	16 (38.1)	6 (13.0)	0.005

COD: confirmed occlusion duration; IOD: indeterminate occlusion duration; PCI: percutaneous coronary intervention; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker.

Table 2 Angiographic characteristics.

Characteristic		COD (n = 122)			
	Total (n = 168)	< 12 months (n = 80)	≥ 12 months (n = 42)	IOD (n = 46)	<i>p</i> -value
Artery with CTO, n (%)					0.62
Left anterior descending artery	71 (42.3)	37 (46.3)	18 (42.9)	16 (34.8)	
Left circumflex artery	28 (16.7)	14 (17.5)	5 (11.9)	9 (19.6)	
Right coronary artery	69 (41.1)	29 (36.2)	19 (45.2)	21 (45.7)	
Number of diseased vessels ^a , n (%)					0.36
1	93 (55.4)	46 (57.5)	24 (57.1)	23 (50.0)	
2	62 (36.9)	30 (37.5)	16 (38.1)	16 (34.8)	
3	13 (7.7)	4 (5.0)	2 (4.8)	7 (15.2)	
Lesion length ^b , mm	17.0 ± 13.6	15.8 ± 12.4	23.9 ± 19.9	16.7 ± 13.0	0.35
Lesion ≥ 20 mm, n (%)	21 (18.1)	11 (17.7)	3 (25.0)	7 (16.7)	0.78
Vessel diameter ^b , mm	2.90 ± 0.58	2.85 ± 0.52	2.93 ± 0.71	2.96 ± 0.63	0.76
Vessel ≤ 2.5 mm, n (%)	30 (25.9)	15 (24.2)	3 (25.0)	12 (28.6)	0.90
Vessel ≥ 3.5 mm, n (%)	19 (16.4)	8 (12.9)	3 (25.0)	8 (19.0)	0.43
Calcification ^b , n (%)	24 (20.7)	11 (17.7)	6 (50.0)	7 (16.7)	0.04
Blunt stump morphology ^b , n (%)	26 (22.4)	16 (25.8)	2 (16.7)	8 (19.0)	0.71
Lesion location, n (%)					0.02
Ostial	19 (11.3)	8 (10.0)	5 (11.9)	6 (13.0)	
Proximal	53 (31.5)	24 (30.0)	13 (31.0)	16 (34.8)	
Medial	85 (50.6)	48 (60.0)	20 (47.6)	17 (37.0)	
Distal	11 (6.5)	0 (0.0)	4 (9.5)	7 (15.2)	
Lesion tortuosity ^b , n (%)	8 (6.9)	4 (6.5)	0 (0.0)	4 (9.5)	0.65
Collateral circulationb, n (%)					0.86
Grade 2	18 (15.5)	11 (17.7)	2 (16.7)	5 (11.9)	
Grade 3	84 (72.4)	43 (69.4)	8 (66.7)	33 (78.6)	
Bridge collateralsb, n (%)	37 (31.9)	18 (29.0)	3 (25.0)	16 (38.1)	0.59
Lateral branch ^b , n (%)	42 (36.2)	24 (38.7)	3 (25.0)	15 (35.7)	0.72

COD: confirmed occlusion duration; IOD: indeterminate occlusion duration; CTO: chronic total occlusion.

none of which required pericardiocentesis. Contrast-induced nephropathy rates (8.7% vs. 2.4% vs. 13.0%; p = 0.19) did not differ between the groups.

The median clinical follow-up was 21.3 months (interquartile range: 5.9 to 36.5 months). There was no significant difference between groups at the end of follow-up regarding rates of MACE (18.8% vs. 7.1% vs. 15.3%; p = 0.23), death (3.7% vs. 0% vs. 4.3%; p = 0.59), AMI (7.5% vs. 4.8% vs. 8.7%; p = 0.86), or new TVR (11.2% vs. 2.4% vs. 6.5%; p = 0.23; Table 4 and Fig. 2A). Similarly, there was no significant difference in the cumulative rate of

MACE at the end of follow-up between patients who had a successful PCI and those who did not (21.8% vs. 20.7%; *hazard ratio* - HD = 1.41; 95% confidence interval - 95% CI 0.42-4.18, log-rank p = 0.41; Fig. 2B).

Predictors associated with angiographic failure in the univariate model were lesion length ≥ 20 mm, reference vessel diameter ≤ 2.5 mm, calcified lesion, multivessel coronary disease, presence of tortuosity in the occluded segment, and chronic renal failure. Of these, lesion length ≥ 20 mm (OR = 7.27; 95% CI 1.94-29.1; p = 0.003), presence of calcification (OR = 4.72; 95% CI 1.19-19.1; p = 0.02), and tortuosity in

 $[\]alpha$ With luminal reduction ≥ 70% at angiography.

b Angiographic characteristics available in 116 patients.

Table 3 Characteristics of procedure.

		COD (r	n = 122)		
Characteristic	Total (n = 168)	< 12 months (n = 80)	≥ 12 months (n = 42)	IOD (n = 46)	<i>p</i> -value
Angiographic success, n (%)	133 (79.2)	64 (80.0)	31 (73.8)	39 (82.6)	0.57
Cause of failure ^a , n (%)					0.09
Guidewire did not cross the lesion	24 (68.6)	12 (75.0)	9 (81.8)	3 (37.5)	
Coronary perforation	3 (8.6)	0 (0.0)	1 (9.1)	2 (25.0)	
Residual lesion	4 (11.4)	2 (12.5)	0 (0.0)	2 (25.0)	
Other	4 (11.4)	2 (12.5)	1 (9.1)	1 (12.5)	
Sheath, n (%)					0.67
6 F	159 (94.6)	77 (96.3)	39 (92.9)	43 (93.5)	
7 F	9 (5.4%)	3 (3.7)	3 (7.1)	3 (6.5)	
Type of access, n (%)					0.60
Femoral	99 (58.9)	49 (61.2)	22 (52.4)	28 (60.9)	
Radial	69 (41.1)	31 (38.8)	20 (47.6)	18 (39.1)	
Number of implanted stents per treated	1.2 ± 0.8	1.3 ± 0.8	1.1 ± 1.0	1.0 ± 0.5	0.30
vessel ^b					
Stent length ^b , mm	31.3 ± 18.0	32.4 ± 18.2	30.3 ± 22.7	30.5 ± 11.9	0.85
Stent diameter ^b , mm	3.7 ± 2.0	4.0 ± 2.1	3.6 ± 2.4	3.5 ± 1.3	0.51
Contrast volume, mL	124.2 ± 61.2	117.2 ± 58.5	144.2 ± 64.6	118.3 ± 59.9	0.02
Stent type ^b , n (%)					< 0.001
Drug-eluting stent	91 (59.9)	34 (47.9)	35 (89.7)	22 (52.4)	
Bare metal stent	61 (40.1)	37 (52.1)	4 (10.3)	20 (47.6)	

COD: confirmed occlusion duration; IOD: indeterminate occlusion duration.

Table 4 In-hospital and late clinical outcomes.

	COD (n = 122)				
Clinical outcome	Total (n = 168)	< 12 months (n = 80) ≥ 12 months (n = 42)		IOD (n = 46)	p-value
In-hospital outcomes					
MACE, n (%)	8 (4.8)	4 (5.0)	1 (2.4)	3 (6.5)	0.73
Death, n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	NA
AMI, n (%)	8 (4.8)	4 (5.0)	1 (2.4)	3 (6.5)	0.73
Target vessel revascularization, n (%)	1 (0.6)	1 (1.2)	0 (0.0)	0 (0.0)	0.99
Contrast-induced nephropathy, n (%)	14 (8.3)	7 (8.7)	1 (2.4)	6 (13.0)	0.19
Late outcomes					
MACE, n (%)	25 (14.9)	15 (18.8)	3 (7.1)	7 (15.2)	0.23
Death, n (%)	5 (3.0)	3 (3.7)	0 (0.0)	2 (4.3)	0.59
AMI, n (%)	12 (7.1)	6 (7.5)	2 (4.8)	4 (8.7)	0.86
Target vessel revascularization, n (%)	13 (7.7)	9 (11.2)	1 (2.4)	3 (6.5)	0.23

COD: confirmed occlusion duration; IOD: indeterminate occlusion duration; MACE: major adverse cardiovascular events; NA: not applicable; AMI: acute myocardial infarction.

Table 5 Independent predictors of angiographic failure.

Variable	OR	95% CI	p-value
Lesion length ≥ 20 mm	7.14	1.90-28.70	0.004
Vessel diameter ≤ 2.5 mm	3.27	0.88-12.21	0.07
Presence of calcification	4.53	1.10-18.83	0.03
Multivessel coronary disease	2.66	0.99-7.79	0.056
Lesion tortuosity	16.33	2.22-149.4	0.02
Chronic renal failure	0.84	0.10-5.46	0.86
Occlusion duration (months)	1.47	0.14-2.46	0.72

Hosmer-Lemeshow statistics = 0.14.

OR: odds ratio; 95% CI: 95% confidence interval.

the occluded segment (OR = 15.98; 95% CI 2.18-144.7; p = 0.007) were independent predictors of angiographic failure in the multivariate model (Table 5).

Discussion

The present study has several important findings. First, a success rate of 79.2% in PCI was identified in a selection of contemporary

patients with coronary lesions with CTO using the antegrade approach, which is comparable to those found in other recent large studies.²³⁻²⁶ Additionally, this study showed that PCI in CTO is a safe procedure with a low rate of in-hospital complications, no deaths, and no need for emergency coronary artery bypass surgery or cardiac tamponade requiring pericardial drainage during in-hospital stay, a finding similar to that of previous studies.^{17,27,28}

The main finding of this study was that neither a long occlusion duration nor IOD affected the success rate or the long-term prognosis of patients undergoing PCI in CTO. The analysis of initial studies showed an association between long occlusion duration and angiographic failure of the procedure.^{15,16} More recently, Olivari et al. showed that occlusion duration superior to 6 months was associated with percutaneous intervention failure in an analysis of 376 consecutive patients with CTO, although, in that study, not all patients had occlusion duration superior to 3 months.²⁹ Similarly, Barlis at al. demonstrated that an IOD determines a five-fold increase in the risk of angiographic failure in an analysis of 202 patients undergoing PCI in CTO.¹⁷ Currently, with the increased experience of interventionists and the development and improvement of new devices, the occlusion duration has

^a Relating to total of 35 interventions without success.

^b Total of 152 implanted stents.




Figure 2. Cumulative rate curves of major adverse cardiovascular events (MACE) between the groups, according to the estimated occlusion duration (A) and failure or success in the procedure (B). PCI: percutaneous coronary intervention; HR: hazard ratio.

shown less impact on the success rate of PCI in CTO. In fact, To-masello at al. showed no association between estimated occlusion duration, or even IOD, and procedural success rate in the analysis of 303 patients with CTO,¹⁸ in agreement with the results of the present study, which showed that the occlusion duration should not be considered as determining factor for decision-making regarding intervention in CTO.

The prognostic effect of PCI in CTO remains controversial and to date there is no published randomized study to elucidate this question. Many nonrandomized studies have shown favorable results in the short and long-term prognosis for patients successfully submitted to PCI in CTO, when compared to those whose procedure was unsuccessful. 14,17,23,24,29 Similarly, recent meta-analyses have shown that successful PCI in CTO is associated with lower rates of mortality, need for revascularization, and residual or recurrent angina, with no difference in the AMI rate when compared to patients with procedural failure. 12,30,31 However, the present study showed no difference in the late follow-up regarding the rate of combined events of death from any cause, AMI, or new TVR between patients who had successful PCI, when compared to those with procedural failure. Possible explanations for this divergent finding of literature are the observational and retrospective design of most previous studies, as well as of the present study, which may have introduced a selection bias, creating heterogeneous groups that may have generated differences in prognosis after the intervention; the size of this study's population may not have been enough to detect a significant difference in the clinical event rate, even with a long-term follow-up; and finally, the use of different definitions of clinical outcomes between studies.

Several angiographic variables were identified in previous studies as independent predictors of procedural failure, such as lesion with long occlusion segment, presence of calcification, tortuosity in the lesion segment, lateral branch at the occlusion site, blunt stump, small reference vessel diameter, multivessel disease, and ostial location of the occlusion. 17,18,23,32,33 The present study confirmed some of these variables (long occlusion segment, tortuosity in the lesion segment and presence of calcification).

However, making comparisons of predictors among various studies may be difficult, because most studies have a small number of patients and consequently little statistical power to identify independent predictors. Moreover, the duration definition for CTO shows significant difference between studies, ranging from 2 weeks to 3 months as a criterion to define CTO. Furthermore, many studies showed incomplete angiographic data, with different definitions for lesion characteristics and inclusion of patients with TIMI grade 1 flow in the analyses.

Limitations

The present study has some limitations, as follows: first, its non-randomized and retrospective study design may have introduced a selection bias; second, the results reflected the experience of a single center, with intermediate-volume CTO operators; third, the low rate of the retrograde technique use, which is associated with higher success rates, may also have affected the results; and finally, due to the small sample size, this study did not have enough statistical power to draw conclusions on the rate of clinical events between the assessed groups and thus, the findings are considered only as hypothesis generator.

Conclusions

Occlusion duration was associated with neither increased failure rate of the procedure nor worse late outcomes in patients submitted to percutaneous coronary intervention in chronically occluded coronary arteries. Therefore, occlusion duration should not limit the therapeutic approach in patients with chronic total occlusions.

Funding source

None declared.

Conflicts of interest

The authors declare no conflicts of interest.

References

- Christofferson RD, Lehmann KG, Martin GV, Every N, Caldwell JH, Kapadia SR. Effect of chronic total coronary occlusion on treatment strategy. Am J Cardiol. 2005;95(9):1088-91.
- Hoye A, van Domburg RT, Sonnenschein K, Serruys PW. Percutaneous coronary intervention for chronic total occlusions: the Thoraxcenter experience 1992– 2002. Eur Hear J. 2005;26(24):2630-6.
- Puma JA, Sketch Jr. MH, Tcheng JE, Harrington RA, Phillips HR, Stack RS, et al. Percutaneous revascularization of chronic coronary occlusions: an overview. J Am Coll Cardiol 1995;26(1):1-11.
- Grantham JA, Marso SP, Spertus J, House J, Holmes Jr. DR, Rutherford BD. Chronic total occlusion angioplasty in the United States. JACC Cardiovasc Interv 2009;2(6):479–86.
- Bufe A, Haltern G, Dinh W, Wolfertz J, Schleiting H, Guelker H. Recanalisation of coronary chronic total occlusions with new techniques including the retrograde approach via collaterals. Neth Hear J. 2011;19(4):162-7.
- Yamane M, Muto M, Matsubara T, Nakamura S, Muramatsu T, Oida A, et al. Contemporary retrograde approach for the recanalisation of coronary chronic total occlusion: on behalf of the Japanese Retrograde Summit Group. EuroIntervention. 2013;9(1):102-9.
- 7. Hsu JT, Tamai H, Kyo E, Tsuji T, Watanabe S. Traditional antegrade approach versus combined antegrade and retrograde approach in the percutaneous treatment of coronary chronic total occlusions. Catheter Cardiovasc Interv. 2009;74(4):555-63.
- Kandzari DE, Rao SV, Moses JW, Dzavik V, Strauss BH, Kutryk MJ, et al; ACROSS/ TOSCA-4 Investigators. Clinical and angiographic outcomes with sirolimuseluting stents in total coronary occlusions: the ACROSS/TOSCA-4 (Approaches to Chronic Occlusions With Sirolimus-Eluting Stents/Total Occlusion Study of Coronary Arteries-4) trial. JACC Cardiovasc Interv. 2009;2(2):97-106.
- Sachdeva R, Agrawal M, Flynn SE, Werner GS, Uretsky BF. The myocardium supplied by a chronic total occlusion is a persistently ischemic zone. Catheter Cardiovasc Interv. 2014;83(1):9-16.
- Pujadas S, Martin V, Rossello X, Carreras F, Barros A, Leta R, et al. Improvement of myocardial function and perfusion after successful percutaneous revascularization in patients with chronic total coronary occlusion. Int J Cardiol. 2013;169(2):147-52.
- 11. Khan KN, Khan MH, Haque MZ. Immediate outcome of chronic total occlusion opening in post-angioplasty patients. Mymensingh Med J. 2013;22(3):489-95.
- Khan MF, Wendel CS, Thai HM, Movahed MR. Effects of percutaneous revascularization of chronic total occlusions on clinical outcomes: a metaanalysis comparing successful versus failed percutaneous intervention for chronic total occlusion. Catheter Cardiovasc Interv. 2013;82(1):95-107.
- 13. Pancholy SB, Boruah P, Ahmed I, Kwan T, Patel TM, Saito S. Meta-analysis of effect on mortality of percutaneous recanalization of coronary chronic total occlusions using a stent-based strategy. Am J Cardiol. 2013;111(4):521-5.
- 14. Yamamoto E, Natsuaki M, Morimoto T, Furukawa Y, Nakagawa Y, Ono K, et al; CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators. Long-term outcomes after percutaneous coronary intervention for chronic total occlusion (from the CREDO-Kyoto Registry Cohort-2). Am J Cardiol. 2013;112(6):767-74.
- 15. Melchior JP, Meier B, Urban P, Finci L, Steffenino G, Noble J, et al. Percutaneous transluminal coronary angioplasty for chronic total coronary arterial occlusion. Am | Cardiol. 1987;59(6):535-8.
- Holmes DR Jr, Vlietstra RE, Reeder GS, Bresnahan JF, Smith HC, Bove AA, et al. Angioplasty in total coronary artery occlusion. J Am Coll Cardiol. 1984;3(3):845-9.

- 17. Barlis P, Kaplan S, Dimopoulos K, Tanigawa J, Schultz C, Di Mario C. An indeterminate occlusion duration predicts procedural failure in the recanalization of coronary chronic total occlusions. Catheter Cardiovasc Interv. 2008;71(5):621-8.
- 18. Tomasello SD, Costanzo L, Campisano MB, Barrano G, Capodanno D, Tamburino C, et al. Does occlusion duration influence procedural and clinical outcome of patients who underwent percutaneous coronary intervention for chronic total occlusion?. J Interv Cardiol. 2011;24(3):223-31.
- 19. Di Mario C, Werner GS, Sianos G, Galassi AR, Büttner J, Dudek D, et al. European perspective in the recanalisation of chronic total occlusions (CTO): consensus document from the EuroCTO Club. EuroIntervention. 2007;3(1):30-43.
- 20. Stone GW, Kandzari DE, Mehran R, Colombo A, Schwartz RS, Bailey S, et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. Circulation. 2005;112(15):2364-72.
- 21. Rentrop KP, Cohen M, Blanke H, Phillips RA. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol. 1985;5(3):587-92.
- McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, et al; CIN Consensus Working Panel. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol. 2006;98(6A):5K-13K.
- Dong S, Smorgick Y, Nahir M, Lotan C, Mosseri M, Nassar H, et al. Predictors for successful angioplasty of chronic totally occluded coronary arteries. J Interv Cardiol. 2005;18(1):1-7.
- 24. Mehran R, Claessen BE, Godino C, Dangas GD, Obunai K, Kanwal S, et al.; Multinational Chronic Total Occlusion Registry. Long-term outcome of percutaneous coronary intervention for chronic total occlusions. JACC Cardiovasc Interv. 2011;4(9):952–61.
- 25. Mehran R, Claessen BE, Godino C, Dangas GD, Obunai K, Kanwal S, et al; Multinational Chronic Total Occlusion Registry. Procedural outcomes and longterm survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience. J Am Coll Cardiol. 2001;38(9):409-14.
- 26. Aziz S, Ramsdale DR. Chronic total occlusions a stiff challenge requiring a major breakthrough: is there light at the end of the tunnel? Heart. 2005;91Suppl 3:iii42-8.
- 27. Noguchi T, Miyazaki MD S, Morii I, Daikoku S, Goto Y, Nonogi H. Percutaneous transluminal coronary angioplasty of chronic total occlusions. Determinants of primary success and long-term clinical outcome. Catheter Cardiovasc Interv. 2000;49:258–64.
- Rathore S, Matsuo H, Terashima M, Kinoshita Y, Kimura M, Tsuchikane E, et al. Procedural and in-hospital outcomes after percutaneous coronary intervention for chronic total occlusions of coronary arteries 2002 to 2008. Impact of novel guidewire techniques. JACC Cardiovasc Interv. 2009;2(6):489-97.
- Ölivari Z, Rubartelli P, Piscione F, Ettori F, Fontanelli A, Salemme L, et al; TOAST-GISE Investigators. Immediate results and one-year clinical outcome after percutaneous coronary interventions in chronic total occlusions: data from a multicenter, prospective, observational study (TOAST-GISE). J Am Coll Cardiol. 2003;41(10):1672-8.
- 30. Li R, Yang S, Tang L, Yang Y, Chen H, Guan S, et al. Meta-analysis of the effect of percutaneous coronary intervention on chronic total coronary occlusions. J Cardiothorac Surg. 2014;9:41.
- 31. Joyal D, Afilalo J, Rinfret S. Effectiveness of recanalization of chronic total occlusions: a systematic review and meta-analysis. Am Heart J. 2010;160(1):179-87.
- Salarifar M, Mousavi M-R, Saroukhani S, Nematipour E, Kassaian SE, Alidoosti M, et al. Percutaneous coronary intervention to treat chronic total occlusion: predictors of technical success and one-year clinical outcome. Tex Heart Inst J. 2014:41(1):40-7.
- 33. Stone GW, Colombo A, Teirstein PS, Moses JW, Leon MB, Reifart NJ, et al. Percutaneous recanalization of chronically occluded coronary arteries: procedural techniques, devices, and results. Catheter Cardiovasc Interv. 2005;66(2):217-36.